Firefly Neuroscience announced its Q3 2024 financial results and strategic developments following its successful Nasdaq listing under "AIFF". The company reported a cash position of $1.2 million as of September 30, 2024, with 8,503,365 shares of common stock outstanding as of November 12.The company has established significant partnerships with pharmaceutical companies including Bright Minds Bioscience, Novartis, and Takeda, leveraging its FDA-cleared Brain Network Analytics (BNA™) technology. Notable collaborations include analyzing data for Bright Minds' Phase 2 trial of BMB-101 in epilepsy and supporting Arrivo BioVentures' Phase 1 study of SP-624 for women's depression treatment.Firefly continues to execute its dual commercialization strategy, focusing on supporting US neurologists in patient care and collaborating with pharmaceutical companies for drug development. The company's proprietary database includes over 77,000 EEG scans across twelve disorders, positioning it for growth in both clinical diagnostics and drug development sectors.

Firefly Neuroscience announced its Q3 2024 financial results and strategic developments following its successful Nasdaq listing under "AIFF". The company reported a cash position of $1.2 million as of September 30, 2024, with 8,503,365 shares of common stock outstanding as of November 12.The company has established significant partnerships with pharmaceutical companies including Bright Minds Bioscience, Novartis, and Takeda, leveraging its FDA-cleared Brain Network Analytics (BNA™) technology. Notable collaborations include analyzing data for Bright Minds' Phase 2 trial of BMB-101 in epilepsy and supporting Arrivo BioVentures' Phase 1 study of SP-624 for women's depression treatment.Firefly continues to execute its dual commercialization strategy, focusing on supporting US neurologists in patient care and collaborating with pharmaceutical companies for drug development. The company's proprietary database includes over 77,000 EEG scans across twelve disorders, positioning it for growth in both clinical diagnostics and drug development sectors.